Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®)
PHASE3CompletedINTERVENTIONAL
Enrollment
10
Participants
Timeline
Start Date
January 31, 2007
Primary Completion Date
December 31, 2009
Conditions
Myeloid LeukemiaMyelodysplastic Syndrome
Interventions
DRUG
5-Azacytidin
in case of decreasing CD34 chimerism
Trial Locations (1)
01307
University hospital Dresden, department of medicine, Dresden
All Listed Sponsors
lead
Technische Universität Dresden
OTHER
NCT00422890 - Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®) | Biotech Hunter | Biotech Hunter